You are here: Industry Insights > OX40

News List

"Reverse Merger" Wave Rises: what's the Logic behind It? Yefenghong
January 23, 2025
Ikena Oncology and Inmagene signed a merger deal. The new firm focuses on IMG-007 for atopic dermatitis. Reverse mergers among Chinese pharma firms are rising.
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis prnasia
June 02, 2021
Amgen and Kyowa Kirin Co., Ltd. announced an agreement to jointly develop and commercialize KHK4083, which is Kyowa Kirin's potential first-in-class, Phase 3-ready anti-OX40 fully human monoclonal antibody in development for the treatment of ...
F-star Therapeutics Announces First Patient Dosed in FS120 Trial americanpharmaceuticalreview
December 24, 2020
F-star Therapeutics has announced the first patient has been dosed in its Phase 1 trial evaluating FS120, a first-in-class dual-agonist tetravalent bispecific antibody targeting CD137 (4-1BB, TNFRSF9) and OX40 (CD134, TNFRSF4).